A multifunctional bispecific antibody protects against Pseudomonas aeruginosa

Science Translational Medicine

Volumn 6, Issue 262, 2014, Pages

  DiGiandomenico, Antonio ^a   Keller, Ashley E ^a   Gao, Cuihua ^a   Rainey, Godfrey J ^a   Warrener, Paul ^a   Camara, Mareia M ^a   Bonnell, Jessica ^a   Fleming, Ryan ^a   Bezabeh, Binyam ^a   Dimasi, Nazzareno ^a   Sellman, Bret R ^a   Hilliard, Jamese ^a   Guenther, Caitlin M ^a   Datta, Vivekananda ^a   Zhao, Wei ^a   Gao, Changshou ^a   Yu, Xiang Qing ^a   Suzich, JoAnn A ^a   Stover, C Kendall ^a  

^a MEDIMMUNE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPECIFIC ANTIBODY; CIPROFLOXACIN; EXOPOLYSACCHARIDE; IMMUNOGLOBULIN G; MEDI 3902; MEROPENEM; MONOCLONAL ANTIBODY; TOBRAMYCIN; UNCLASSIFIED DRUG; VIRULENCE FACTOR; ANTIINFECTIVE AGENT; BACTERIAL ANTIGEN; BACTERIUM ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DRUG POTENTIATION; DRUG TARGETING; MOUSE; MOUSE MODEL; NONHUMAN; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; PSEUDOMONAS PNEUMONIA; TYPE III SECRETION SYSTEM; ANIMAL; CHEMISTRY; CONFORMATION; DISEASE MODEL; HUMAN; IMMUNOLOGY; PHAGOCYTOSIS; PSEUDOMONAS INFECTIONS; TUMOR CELL LINE;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTIBODIES, BACTERIAL; ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL; ANTIGENS, BACTERIAL; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, BACTERIAL; HUMANS; MICE; MOLECULAR CONFORMATION; PHAGOCYTOSIS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 84910673427     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3009655     Document Type: Article

References (46)

1. A. Casadevall, M. D. Scharff, Serum therapy revisited: Animal models of infection and development of passive antibody therapy. Antimicrob. Agents Chemother. 38, 1695-1702 (1994).
2. A. Casadevall, M. D. Scharff, Return to the past: The case for antibody-based therapies in infectious diseases. Clin. Infect. Dis. 21, 150-161 (1995).
3. J. N. Pendleton, S. P. Gorman, B. F. Gilmore, Clinical relevance of the ESKAPE pathogens. Expert Rev. Anti. Infect. Ther. 11, 297-308 (2013).
4. P. Speck, Antibiotics: Avert an impending crisis. Nature 496, 169 (2013).
5. The antibiotic alarm. Nature 495, 141 (2013).
6. A. DiGiandomenico, P. Warrener, M. Hamilton, S. Guillard, P. Ravn, R. Minter, M. M. Camara, V. Venkatraman, R. S. Macgill, J. Lin, Q. Wang, A. E. Keller, J. C. Bonnell, M. Tomich, L. Jermutus, M. P. McCarthy, D. A. Melnick, J. A. Suzich, C. K. Stover, Identification of broadly protective human antibodies to Pseudomonas aeruginosa exopolysaccharide Psl by phenotypic screening. J. Exp. Med. 209, 1273-1287 (2012).
7. K. D. Jackson, M. Starkey, S. Kremer, M. R. Parsek, D. J. Wozniak, Identification of psl, a locus encoding a potential exopolysaccharide that is essential for Pseudomonas aeruginosa PAO1 biofilm formation. J. Bacteriol. 186, 4466-4475 (2004).
8. M. Mishra, M. S. Byrd, S. Sergeant, A. K. Azad, M. R. Parsek, L. McPhail, L. S. Schlesinger, D. J. Wozniak, Pseudomonas aeruginosa Psl polysaccharide reduces neutrophil phagocytosis and the oxidative response by limiting complement-mediated opsonization. Cell. Microbiol. 14, 95-106 (2012).
9. B. François, C. E. Luyt, A. Dugard, M. Wolff, J. L. Diehl, S. Jaber, J. M. Forel, D. Garot, E. Kipnis, A. Mebazaa, B. Misset, A. Andremont, M. C. Ploy, A. Jacobs, G. Yarranton, T. Pearce, J. Y. Fagon, J. Chastre, Safety and pharmacokinetics of an anti-PcrV PEGylated monoclonal antibody fragment in mechanically ventilated patients colonized with Pseudomonas aeruginosa: A randomized, double-blind, placebo-controlled trial. Crit. Care Med. 40, 2320-2326 (2012).
10. T. Sawa, T. L. Yahr, M. Ohara, K. Kurahashi, M. A. Gropper, J. P. Wiener-Kronish, D. W. Frank, Active and passive immunization with the Pseudomonas V antigen protects against type III intoxication and lung injury. Nat. Med. 5, 392-398 (1999).
11. P. Warrener, R. Varkey, J. C. Bonnell, A. DiGiandomenico, M. Camara, K. Cook, L. Peng, J. Zha, P. Chowdury, B. Sellman, C. K. Stover, A novel anti-PcrV antibody providing enhanced protection against Pseudomonas aeruginosa in multiple animal infection models. Antimicrob. Agents Chemother. 58, 4384-4391 (2014).
12. A. L. Goodman, B. Kulasekara, A. Rietsch, D. Boyd, R. S. Smith, S. Lory, A signaling network reciprocally regulates genes associated with acute infection and chronic persistence in Pseudomonas aeruginosa. Dev. Cell 7, 745-754 (2004).
13. H. A. Howell, L. K. Logan, A. R. Hauser, Type III secretion of ExoU is critical during early Pseudomonas aeruginosa pneumonia. MBio 4, e00032-13 (2013).
14. H. Mikkelsen, M. Sivaneson, A. Filloux, Key two-component regulatory systems that control biofilm formation in Pseudomonas aeruginosa. Environ. Microbiol. 13, 1666-1681 (2011).
15. I. Ventre, A. L. Goodman, I. Vallet-Gely, P. Vasseur, C. Soscia, S. Molin, S. Bleves, A. Lazdunski, S. Lory, A. Filloux, Multiple sensors control reciprocal expression of Pseudomonas aeruginosa regulatory RNA and virulence genes. Proc. Natl. Acad. Sci. U.S.A. 103, 171-176 (2006).
16. C. Milstein, A. C. Cuello, Hybrid hybridomas and their use in immunohistochemistry. Nature 305, 537-540 (1983).
17. R. E. Bird, K. D. Hardman, J. W. Jacobson, S. Johnson, B. M. Kaufman, S. M. Lee, T. Lee, S. H. Pope, G. S. Riordan, M. Whitlow, Single-chain antigen-binding proteins. Science 242, 423-426 (1988).
18. M. J. Coloma, S. L. Morrison, Design and production of novel tetravalent bispecific antibodies. Nat. Biotechnol. 15, 159-163 (1997).
19. R. E. Kontermann, Dual targeting strategies with bispecific antibodies. MAbs 4, 182-197 (2012).
20. W. Chen, T. Ying, D. S. Dimitrov, Antibody-based candidate therapeutics against HIV-1: Implications for virus eradication and vaccine design. Expert Opin. Biol. Ther. 13, 657-671 (2013).
21. Z. Yang, D. Schmidt, W. Liu, S. Li, L. Shi, J. Sheng, K. Chen, H. Yu, J. M. Tremblay, X. Chen, K. H. Piepenbrink, E. J. Sundberg, C. P. Kelly, G. Bai, C. B. Shoemaker, H. Feng, A novel multi-valent, single-domain antibody targeting TcdA and TcdB prevents fulminant Clostridium difficile infection in mice. J. Infect. Dis. 210, 964-972 (2014).
22. J. M. Tremblay, J. Mukherjee, C. E. Leysath, M. Debatis, K. Ofori, K. Baldwin, C. Boucher, R. Peters, G. Beamer, A. Sheoran, D. Bedenice, S. Tzipori, C. B. Shoemaker, A single VHH-based toxin-neutralizing agent and an effector antibody protect mice against challenge with Shiga toxins 1 and 2. Infect. Immun. 81, 4592-4603 (2013).
23. D. S. Borkar, S. M. Fleiszig, C. Leong, P. Lalitha, M. Srinivasan, A. A. Ghanekar, C. Tam, W. Y. Li, M. E. Zegans, S. D. McLeod, T. M. Lietman, N. R. Acharya, Association between cytotoxic and invasive Pseudomonas aeruginosa and clinical outcomes in bacterial keratitis. JAMA Ophthalmol. 131, 147-153 (2013).
24. H. Feltman, G. Schulert, S. Khan, M. Jain, L. Peterson, A. R. Hauser, Prevalence of type III secretion genes in clinical and environmental isolates of Pseudomonas aeruginosa. Microbiology 147, 2659-2669 (2001).
25. K. W. Garey, Q. P. Vo, M. T. Larocco, L. O. Gentry, V. H. Tam, Prevalence of type III secretion protein exoenzymes and antimicrobial susceptibility patterns from bloodstream isolates of patients with Pseudomonas aeruginosa bacteremia. J. Chemother. 20, 714-720 (2008).
26. A. R. Hauser, The type III secretion system of Pseudomonas aeruginosa: Infection by injection. Nat. Rev. Microbiol. 7, 654-665 (2009).
27. A. Pastor, J. Chabert, M. Louwagie, J. Garin, I. Attree, PscF is a major component of the Pseudomonas aeruginosa type III secretion needle. FEMS Microbiol. Lett. 253, 95-101 (2005).
28. C. Soscia, A. Hachani, A. Bernadac, A. Filloux, S. Bleves, Cross talk between type III secretion and flagellar assembly systems in Pseudomonas aeruginosa. J. Bacteriol. 189, 3124-3132 (2007).
29. N. Dimasi, C. Gao, R. Fleming, R. M. Woods, X. T. Yao, L. Shirinian, P. A. Kiener, H. Wu, The design and characterization of oligospecific antibodies for simultaneous targeting of multiple disease mediators. J. Mol. Biol. 393, 672-692 (2009).
30. V. Finck-Barbançon, J. Goranson, L. Zhu, T. Sawa, J. P. Wiener-Kronish, S. M. Fleiszig, C. Wu, L. Mende-Mueller, D. W. Frank, ExoU expression by Pseudomonas aeruginosa correlates with acute cytotoxicity and epithelial injury. Mol. Microbiol. 25, 547-557 (1997).
31. H. Sato, D. W. Frank, C. J. Hillard, J. B. Feix, R. R. Pankhaniya, K. Moriyama, V. Finck-Barbançon, A. Buchaklian, M. Lei, R. M. Long, J. Wiener-Kronish, T. Sawa, The mechanism of action of the Pseudomonas aeruginosa-encoded type III cytotoxin, ExoU. EMBO J. 22, 2959-2969 (2003).
32. M. H. Tao, S. L. Morrison, Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region. J. Immunol. 143, 2595-2601 (1989).
33. J. M. Scarff, J. B. Goldberg, Vaccination against Pseudomonas aeruginosa pneumonia in immunocompromised mice. Clin. Vaccine Immunol. 15, 367-375 (2008).
34. M. Bodro, N. Sabé, F. Tubau, L. Lladó, C. Baliellas, J. Roca, J. M. Cruzado, J. Carratalà, Risk factors and outcomes of bacteremia caused by drug-resistant ESKAPE pathogens in solidorgan transplant recipients. Transplantation 96, 843-849 (2013).
35. F. Nanvazadeh, A. D. Khosravi, M. R. Zolfaghari, N. Parhizgari, Genotyping of Pseudomonas aeruginosa strains isolated from burn patients by RAPD-PCR. Burns 39, 1409-1413 (2013).
36. J. A. Schaber, W. J. Triffo, S. J. Suh, J. W. Oliver, M. C. Hastert, J. A. Griswold, M. Auer, A. N. Hamood, K. P. Rumbaugh, Pseudomonas aeruginosa forms biofilms in acute infection independent of cell-to-cell signaling. Infect. Immun. 75, 3715-3721 (2007).
37. H. Calum, C. Moser, P. O. Jensen, L. Christophersen, D. S. Maling, M. van Gennip, T. Bjarnsholt, H. P. Hougen, M. Givskov, G. K. Jacobsen, N. Høiby, Thermal injury induces impaired function in polymorphonuclear neutrophil granulocytes and reduced control of burn wound infection. Clin. Exp. Immunol. 156, 102-110 (2009).
38. Q. Lu, J. J. Rouby, P. F. Laterre, P. Eggimann, A. Dugard, E. J. Giamarellos-Bourboulis, E. Mercier, J. Garbino, C. E. Luyt, J. Chastre, V. Georgescu-Kyburz, M. P. Rudolf, V. Gafner, H. Lazar, H. Koch, A. Perez, S. D. Krämer, M. Tamm, Pharmacokinetics and safety of panobacumab: Specific adjunctive immunotherapy in critical patients with nosocomial Pseudomonas aeruginosa O11 pneumonia. J. Antimicrob. Chemother. 66, 1110-1116 (2011).
39. J. L. Vincent, D. J. Bihari, P. M. Suter, H. A. Bruining, J. White, M. H. Nicolas-Chanoin, M. Wolff, R. C. Spencer, M. Hemmer, The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. JAMA 274, 639-644 (1995).
40. L. Ma, K. D. Jackson, R. M. Landry, M. R. Parsek, D. J. Wozniak, Analysis of Pseudomonas aeruginosa conditional Psl variants reveals roles for the Psl polysaccharide in adhesion and maintaining biofilm structure postattachment. J. Bacteriol. 188, 8213-8221 (2006).
41. C. Ryder, M. Byrd, D. J. Wozniak, Role of polysaccharides in Pseudomonas aeruginosa biofilm development. Curr. Opin. Microbiol. 10, 644-648 (2007).
42. S. G. Machado, G. A. Robinson, A direct, general approach based on isobolograms for assessing the joint action of drugs in pre-clinical experiments. Stat. Med. 13, 2289-2309 (1994).
43. R. Chait, A. Craney, R. Kishony, Antibiotic interactions that select against resistance. Nature 446, 668-671 (2007).
44. A. DiGiandomenico, J. Rao, K. Harcher, T. S. Zaidi, J. Gardner, A. N. Neely, G. B. Pier, J. B. Goldberg, Intranasal immunization with heterologously expressed polysaccharide protects against multiple Pseudomonas aeruginosa infections. Proc. Natl. Acad. Sci. U.S.A. 104, 4624-4629 (2007).
45. F. R. Cockerill, M. A. Wikler, J. Alder, M. N. Dudley, G. M. Eliopoulos, M. J. Ferraro, D. J. Hardy, D. W. Hecht, J. A. Hindler, J. B. Patel, M. Powell, J. M. Swenson, R. B. Thomson, M. M. Traczewski, M. P. Weinstein, B. L. Zimmer, Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically; Approved Standard - Ninth Edition (Clinical and Laboratory Standard Institute, Wayne, PA, 2012).
46. D. A. Gilpin, Calculation of a new Meeh constant and experimental determination of burn size. Burns 22, 607-611 (1996).